HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Asthma management: the challenge of equivalence.

Abstract
Increasing prevalence and severity of asthma worldwide encourage the development of new antiasthmatic drugs, alternative treatment regimens and improved formulations of established drugs. Whereas the efficacy of new chemical entities (NCEs) is usually demonstrated by superiority over placebo or a subtherapeutic dose of the active drug, equivalence concepts have to be used in the following situations: the need to replace chlorofluorocarbon (CFC) propellants for inhalative asthma medications by suitable alternatives, and the need to demonstrate that an alternative treatment regimen is not clinically inferior to an established reference treatment. To cover both situations, the recent ICH guidance on biostatistics clearly distinguishes between two-sided equivalence trials and one-sided non-inferiority trials. In this context, non-inferiority always means "not inferior by a clinically relevant amount". After having confirmed non-inferiority, superiority of the alternative test treatment over the reference treatment can additionally be tested without the need to adjust the significance level. The definition of equivalence acceptance limits becomes crucial, particularly in studies conducted in the flat range of the dose-response curve of inhaled steroids. In order to assess the non-inferiority of steroid sparing add-on treatments we propose a one-sided test based on post-/pre-ratios which have substantially reduced coefficients of variation compared to the post-treatment values themselves. The non-inferiority acceptance limit of 0.90 - as opposed to 0.80 in bioequivalence assessment - reflects clinically irrelevant changes of lung function variables. The proposed methodology is illustrated by 2 examples from randomized, double-blind, parallel-group studies comparing inhaled steroid plus theophylline versus doubling the steroid dose in asthmatics who are symptomatic on low-dose inhaled steroid.
AuthorsV W Steinijans, M Neuhäuser, T Hummel, S Leichtl, F Rathgeb, A Keller
JournalInternational journal of clinical pharmacology and therapeutics (Int J Clin Pharmacol Ther) Vol. 36 Issue 3 Pg. 117-25 (Mar 1998) ISSN: 0946-1965 [Print] Germany
PMID9562226 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Anti-Asthmatic Agents
  • Chlorofluorocarbons
  • Steroids
  • Theophylline
Topics
  • Administration, Inhalation
  • Anti-Asthmatic Agents (administration & dosage, pharmacokinetics)
  • Area Under Curve
  • Asthma (drug therapy)
  • Chlorofluorocarbons
  • Confidence Intervals
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Humans
  • Nebulizers and Vaporizers (standards)
  • Randomized Controlled Trials as Topic (methods)
  • Research Design
  • Sample Size
  • Steroids (administration & dosage, pharmacokinetics)
  • Theophylline (administration & dosage, pharmacokinetics)
  • Therapeutic Equivalency

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: